Praliciguat

Praliciguat, a Clinical-stage sGC Stimulator, Improved Insulin Sensitivity, Lipid Tolerance and Energy Utilization in a Diet-induced Obesity Mouse Model

9th International Conference on cGMP (2019)

Chad D. Schwartzkopf, John R. Hadcock, Julien Roux, Guang Liu, Courtney Shea, Mark G. Currie, G. Todd Milne, Jaime L. Masferrer and Juli E. Jones

Data from this preclinical study suggest that praliciguat may have positive effects on key metabolic parameters.

Praliciguat reduced postprandial circulating triglycerides in a mouse model of type 2 diabetes, suggesting improved lipid handling

Lipid tolerance test in mice fed a normal diet (Lean) or in mice with diet-induced type 2 diabetes, either untreated (Obese) or treated with praliciguat (PRL). A time course of plasma triglycerides (left) and triglycerides area under the curve (AUC; right) are shown. Time course data were analyzed by 2-way repeated measures ANOVA followed by Dunnett’s test. AUC data were analyzed by 1-way ANOVA followed by Dunnett’s test. *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001 vs Obese. Data are shown as Mean+/-SEM. Schwartzkopf et al. (cGMP 2019) oral presentation by Juli Jones

Metabolic effects of praliciguat in preclinical studies

Juli Jones, Cyclerion’s head of pharmacology and presenting author at the 9th International Conference on cGMP, shares more about a preclinical study that demonstrated an association between treatment with praliciguat and improved insulin sensitivity, lower triglycerides, and increased fat oxidation.

Return to Archive
Top